A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.

Also called NCT01043029

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 302 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01043029
Other papers using this trial's data
  • Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study BMC nephrology, 2014-11-18 DOI, PubMed 25407798, PMC4364102 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Brazil, Colombia, El Salvador, Germany, Hong Kong SAR China, Hungary, Italy, Mexico, Peru, Romania, Russia, Slovakia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01043029. Randomized; double masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
aleglitazar
Intervention (Drug)
pioglitazone
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct01043029
Content hash
449b5c436be46a9c6d4763322cb7dd2a04e74832bdff15abe2c1d0fe2ae49dbc